Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS

Xenobiotica

Volumn 43, Issue 12, 2013, Pages 1073-1083

  Youssef, Amir S ^a   Argikar, Upendra A ^b   Pathikonda, Murali ^c   Parkman, Henry P ^c   Nagar, Swati ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Domperidone; Gastroparesis; LC MS MS; Metabolite identification; Prokinetics

Indexed keywords

CYTOCHROME P450 3A4; DOMPERIDONE; DRUG METABOLITE;

ADULT; AGED; ARTICLE; CELL FRACTIONATION; CLINICAL ARTICLE; COLLISIONALLY ACTIVATED DISSOCIATION; CONJUGATION; DEALKYLATION; DIHYDROXYLATION; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG IDENTIFICATION; DRUG RETENTION; DRUG SAFETY; ELECTROSPRAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; OXIDATION; PLASMA; STOMACH PARESIS; TANDEM MASS SPECTROMETRY; URINE;

ADULT; AGED; CHROMATOGRAPHY, LIQUID; DOMPERIDONE; FEMALE; GASTROPARESIS; HUMANS; MALE; MIDDLE AGED; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; YOUNG ADULT;

EID: 84887236077     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.797623     Document Type: Article

References (25)

1. Abell TL, Bernstein RK, Cutts T, et al. (2006). Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 18:263-83.
2. Agarwal S, Gowda KV, Mandal U, et al. (2007). Bioequivalence study of a sustained release fixed dose combination capsule containing esomeprazole and domperidone in healthy subjects. Arzneimittelforschung 57:274-7.
3. Ahmad N, Keith-Ferris J, Gooden E, Abell T. (2006). Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 6:571-6.
4. Bamburowicz-Klimkowska M, Zywiec K, Potentas A, Szutowski M. (2007). Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Rep 59: 752-6.
5. Barone JA. (1999). Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 33:429-40.
6. Chang SY, Fancher RM, Zhang H, Gan J. (2010). Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica 40:138-45.
7. Dan Y, Murakami H, Koyabu N, et al. (2002). Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J Pharm Pharmacol 54:729-33.
8. Friedenberg F, Parkman H. (2006). Delayed gastric emptying: whom to test, how to test, and what to do. Curr Treat Options Gastroenterol 9: 295-304.
9. Friedenberg FK, Parkman HP. (2007). Advances in the management of gastroparesis. Curr Treat Options Gastroenterol 10:283-93.
10. Goodman LS, Hardman JG, Limbird LE, Gilman AG. (2001). Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill.
11. Heykants J, Hendriks R, Meuldermans W, et al. (1981). On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 6:61-70.
12. Jolliet P, Nion S, Allain-Veyrac G, et al. (2007). Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res 56:11-17.
13. Masaoka T, Tack J. (2009). Gastroparesis: current concepts and management. Gut Liver 3:166-73.
14. Meuldermans W, Hurkmans R, Swysen E, et al. (1981). On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 6:49-60.
15. Michaud V, Turgeon J. (2010). Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett 4:69-76.
16. Parkman H, Fass R, Foxx-Orenstein A. (2010). Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol 6:1-16.
17. Parkman HP, Jacobs MR, Mishra A, et al. (2011). Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 56: 115-24.
18. Reddymasu S, Soykan I, McCallum R. (2007). Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102:2036-45.
19. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. (1996). Pglycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-24.
20. Simard C, Michaud V, Gibbs B, et al. (2004). Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 34:1013-23.
21. Stapleton J, Wo JM. (2009). Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointest Endosc Clin N Am 19:57-72, vi.
22. Ward B, Morocho A, Kandil A, et al. (2004). Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277-87.
23. Wu M, Gao L, Cai X, Wang G. (2002). Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. Acta Pharmacol Sin 23:285-8.
24. Zhang D, Zhu M, Humphreys WG. (2008). Drug metabolism in drug design and development: basic concepts and practice. Hoboken (NJ): Wiley-Interscience.
25. Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:289-95.